Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States
Abstract Objective To estimate the proportion of patients hospitalized with COVID-19 who undergo dialysis, tracheostomy, and extracorporeal membrane oxygenation (ECMO).Design A network cohort study.Setting Seven databases from the United States containing routinely-collected patient data: HealthVerity, Premier, IQVIA Hospital CDM, IQVIA Open Claims, Optum EHR, Optum SES, and VA-OMOP.Patients Patients hospitalized with a clinical diagnosis or a positive test result for COVID-19.Interventions Dialysis, tracheostomy, and ECMO.Measurements and Main Results 842,928 patients hospitalized with COVID-19 were included (22,887 from HealthVerity, 77,853 from IQVIA Hospital CDM, 533,997 from IQVIA Open Claims, 36,717 from Optum EHR, 4,336 from OPTUM SES, 156,187 from Premier, and 10,951 from VA-OMOP). Across the six databases, 35,192 (4.17% [95% CI: 4.13% to 4.22%]) patients received dialysis, 6,950 (0.82% [0.81% to 0.84%]) had a tracheostomy, and 1,568 (0.19% [95% CI: 0.18% to 0.20%]) patients underwent ECMO over the 30 days following hospitalization. Use of ECMO was more common among patients who were younger, male, and with fewer comorbidities. Tracheostomy was broadly used for a similar proportion of patients regardless of age, sex, or comorbidity. While dialysis was generally used for a similar proportion among younger and older patients, it was more frequent among male patients and among those with chronic kidney disease.Conclusion Use of dialysis among those hospitalized with COVID-19 is high at around 4%. Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 18. Feb. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2020.11.25.20229088 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI019428979 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI019428979 | ||
003 | DE-627 | ||
005 | 20230429085450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201130s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2020.11.25.20229088 |2 doi | |
035 | |a (DE-627)XBI019428979 | ||
035 | |a (DE-599)biorXiv10.1101/2020.11.25.20229088 | ||
035 | |a (biorXiv)10.1101/2020.11.25.20229088 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Burn, Edward |e verfasserin |4 aut | |
245 | 1 | 0 | |a Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Objective To estimate the proportion of patients hospitalized with COVID-19 who undergo dialysis, tracheostomy, and extracorporeal membrane oxygenation (ECMO).Design A network cohort study.Setting Seven databases from the United States containing routinely-collected patient data: HealthVerity, Premier, IQVIA Hospital CDM, IQVIA Open Claims, Optum EHR, Optum SES, and VA-OMOP.Patients Patients hospitalized with a clinical diagnosis or a positive test result for COVID-19.Interventions Dialysis, tracheostomy, and ECMO.Measurements and Main Results 842,928 patients hospitalized with COVID-19 were included (22,887 from HealthVerity, 77,853 from IQVIA Hospital CDM, 533,997 from IQVIA Open Claims, 36,717 from Optum EHR, 4,336 from OPTUM SES, 156,187 from Premier, and 10,951 from VA-OMOP). Across the six databases, 35,192 (4.17% [95% CI: 4.13% to 4.22%]) patients received dialysis, 6,950 (0.82% [0.81% to 0.84%]) had a tracheostomy, and 1,568 (0.19% [95% CI: 0.18% to 0.20%]) patients underwent ECMO over the 30 days following hospitalization. Use of ECMO was more common among patients who were younger, male, and with fewer comorbidities. Tracheostomy was broadly used for a similar proportion of patients regardless of age, sex, or comorbidity. While dialysis was generally used for a similar proportion among younger and older patients, it was more frequent among male patients and among those with chronic kidney disease.Conclusion Use of dialysis among those hospitalized with COVID-19 is high at around 4%. Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial. | ||
700 | 1 | |a Sena, Anthony G. |e verfasserin |4 aut | |
700 | 1 | |a Prats-Uribe, Albert |e verfasserin |4 aut | |
700 | 1 | |a Spotnitz, Matthew |e verfasserin |4 aut | |
700 | 1 | |a DuVall, Scott |e verfasserin |4 aut | |
700 | 1 | |a Lynch, Kristine E. |e verfasserin |4 aut | |
700 | 1 | |a Matheny, Michael E. |e verfasserin |4 aut | |
700 | 1 | |a Nyberg, Fredrik |e verfasserin |4 aut | |
700 | 1 | |a Ahmed, Waheed-Ul-Rahman |e verfasserin |4 aut | |
700 | 1 | |a Alser, Osaid |e verfasserin |4 aut | |
700 | 1 | |a Alghoul, Heba |e verfasserin |4 aut | |
700 | 1 | |a Alshammari, Thamir |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
700 | 1 | |a Casajust, Paula |e verfasserin |4 aut | |
700 | 1 | |a Areia, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Shah, Karishma |e verfasserin |4 aut | |
700 | 1 | |a Reich, Christian |e verfasserin |4 aut | |
700 | 1 | |a Blacketer, Clair |e verfasserin |4 aut | |
700 | 1 | |a Andryc, Alan |e verfasserin |4 aut | |
700 | 1 | |a Fortin, Stephen |e verfasserin |4 aut | |
700 | 1 | |a Natarajan, Karthik |e verfasserin |4 aut | |
700 | 1 | |a Gong, Mengchun |e verfasserin |4 aut | |
700 | 1 | |a Golozar, Asieh |e verfasserin |4 aut | |
700 | 1 | |a Morales, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Rijnbeek, Peter |e verfasserin |4 aut | |
700 | 1 | |a Subbian, Vignesh |e verfasserin |4 aut | |
700 | 1 | |a Roel, Elena |e verfasserin |4 aut | |
700 | 1 | |a Recalde, Martina |e verfasserin |4 aut | |
700 | 1 | |a Lane, Jennifer C.E. |e verfasserin |4 aut | |
700 | 1 | |a Vizcaya, David |e verfasserin |4 aut | |
700 | 1 | |a Posada, Jose D. |e verfasserin |4 aut | |
700 | 1 | |a Shah, Nigam H. |e verfasserin |4 aut | |
700 | 1 | |a Jonnagaddala, Jitendra |e verfasserin |4 aut | |
700 | 1 | |a Lai, Lana Yin Hui |e verfasserin |4 aut | |
700 | 1 | |a Avilés-Jurado, Francesc Xavier |e verfasserin |4 aut | |
700 | 1 | |a Hripcsak, George |e verfasserin |4 aut | |
700 | 1 | |a Suchard, Marc A. |e verfasserin |4 aut | |
700 | 1 | |a Ranzani, Otavio T. |e verfasserin |4 aut | |
700 | 1 | |a Ryan, Patrick |e verfasserin |4 aut | |
700 | 1 | |a Prieto-Alhambra, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Kostka, Kristin |e verfasserin |4 aut | |
700 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 18. Feb. |
773 | 1 | 8 | |g year:2021 |g day:18 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.11.25.20229088 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 18 |c 02 | ||
953 | |2 045F |a 570 |